Nursing Support for mCRPC Patients During Radiopharmaceutical Treatment
Nursing Support for mCRPC Patients During Radiopharmaceutical Treatment
A clinical update for oncology nurses
A clinical update for oncology nurses
Janet Forgenie
In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC).
Watch the video and download the accompanying slides to learn about:
- The considerations for treatment selection in clinical practice to minimise the impact on patients' lives
- Applying recent data to treatment sequencing in bone-dominant mCRPC
- Educating and supporting patients during treatment so they know what to expect
Janet Forgenie
Uro-Oncology Clinical Nurse Specialist
University College Hospital
United Kingdom (UK)
Janet Forgenie works at University College Hospital London as a Uro-oncology CNS managing patients with organ confined disease as well as metastatic disease having chemotherapy, radiotherapy and immunotherapy treatments primarily for prostate but also with bladder and penile cancer. She has a specialist interest in penile cancer patients who undergo extensive treatment regimens with complex health care needs. Over the years as a uro-oncology CNS Janet has been involved in setting up patient support groups and information seminars for radiotherapy patients which have proven very successful. She has also been involved in an exercise pilot for prostate patients on hormone treatments to encourage exercise to help manage some of the unpleasant side effects from hormones, such as bone health, body image and weight gain. Her background of diagnostic urology has helped extensively in the management of prostate cancer patients, and as a nurse prescriber Janet feels this has been invaluable in the development of a truly independent nurse led service. Janet started her nursing career in Canterbury Kent, achieving her Nursing Diploma in 1994 and Degree in 1997. During her nursing career Janet has worked primarily within urology and oncology, and her current role as a Uro-oncology CNS that combines both specialities is ideal. Janet’s urology experience has been extensive over the past 26 years, working with benign urology as well as oncology urology. She has experience with diagnostic urology, urodynamics and continence and bladder function and has also been involved in pathway development and service development. Janet also has three years of oncology experience, one of which was spent in Australia working with chemotherapy patients and the other two working on an inpatient chemotherapy ward.
Janet Forgenie has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Astellas, Bayer
Nursing Support for mCRPC patients during radiopharmaceutical treatment
Video |
3 min
|
Jul 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Clinical Takeaways
-
Radiopharmaceuticals such as radium-223 and 177Lu-PSMA-617 offer a survival benefit to mCRPC patients as well as managing bone pain and QOL
-
They are able to deliver targeted radiation to prostate cancer cells, thereby minimising toxicity to normal healthy tissue
-
Real-world data support using 177Lu-PSMA in patients who previously received Ra-223
-
Nurses and patients should be aware of post-treatment precautions, but radiopharmaceuticals are an effective and manageable treatment option for mCRPC patients
This educational programme is supported by an Independent Medical Education Grant from Bayer
GU NURSES CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.